Biomarker discovery in ovarian cancer

Women's Health

Volumn 4, Issue 1, 2008, Pages 27-40

  Tung, Celestine S ^a   Wong, Kwong Kwok ^c   Mok, Samuel C ^b  

^a UNIVERSITY OF TEXAS   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c NONE

Author keywords

Biomarker; Genomics; Ovarian cancer; Proteomics

Indexed keywords

APOLIPOPROTEIN A1; BIOLOGICAL MARKER; CA 125 ANTIGEN; COLONY STIMULATING FACTOR 1; COMPLEMENTARY DNA; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FIBROBLAST GROWTH FACTOR 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; KALLIKREIN; MATRIX METALLOPROTEINASE; OSTEOPONTIN; PROTEIN BCL 2; PROTEIN P53; RNA; SURVIVIN; TUBULIN; VASCULOTROPIN; X LINKED INHIBITOR OF APOPTOSIS;

ADVANCED CANCER; BIOINFORMATICS; CANCER DIAGNOSIS; CANCER SCREENING; CANCER STAGING; CLINICAL TRIAL; COMPARATIVE GENOMIC HYBRIDIZATION; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DNA MICROARRAY; DNA SEQUENCE; GENE EXPRESSION PROFILING; GENETIC ANALYSIS; GENOMICS; HETEROZYGOSITY LOSS; HUMAN; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; METABOLOMICS; NON INVASIVE MEASUREMENT; OVARY CANCER; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEOMICS; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; TREATMENT RESPONSE; TWO DIMENSIONAL GEL ELECTROPHORESIS;

CA-125 ANTIGEN; FEMALE; HUMANS; LOSS OF HETEROZYGOSITY; OVARIAN NEOPLASMS; PROGNOSIS; PROTEOMICS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 38049141285     PISSN: 17455057     EISSN: 17455065     Source Type: Journal    
DOI: 10.2217/17455057.4.1.27     Document Type: Review

References (135)

1. Hoskins WJ: Prospective on ovarian cancer: why prevent? J. Cell Biochem. Suppl. 23, 189-199 (1995).
2. Biomarkers Definitions Working Group: Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin. Pharmacol. Ther. 69(3), 89-95 (2001).
3. Bast RC Jr, Urban N, Shridhar V et al.: Early detection of ovarian cancer: promise and reality. Cancer Treat. Res. 107, 61-97 (2002).
4. Jacobs IJ, Menon U: Progress and challenges in screening for early detection of ovarian cancer. Mol. Cell Proteomics 3(4), 355-366 (2004).
5. Ye B, Gagnon A, Mok SC: Recent technical strategies to identify diagnostic biomarkers for ovarian cancer. Expert Rev. Proteomics 4(1), 121-131 (2007).
6. Cavenee WK, Dryja TP, Phillips RA et al.: Expression of recessive alleles by chromosomal mechanisms in retinoblastoma. Nature 305(5937), 779-784 (1983).
7. Doxsey S: The centrosome - a tiny organelle with big potential. Nat. Genet. 20(2), 104-106 (1998).
8. Thiagalingam S, Laken S, Willson JK et al.: Mechanisms underlying losses of heterozygosity in human colorectal cancers. Proc. Natl Acad. Sci. USA 98(5), 2698-702 (2001).
9. Liu Y, Ganesan TS: Tumour suppressor genes in sporadic epithelial ovarian cancer. Reproduction 123(3), 341-353 (2002).
10. Auersperg N, Edelson MI, Mok SC, Johnson SW, Hamilton TC: The biology of ovarian cancer. Semin. Oncol. 25(3), 281-304 (1998).
11. Gorringe KL, Jacobs S, Thompson ER et al.: High-resolution single nucleotide polymorphism array analysis of epithelial ovarian cancer reveals numerous microdeletions and amplifications. Clin. Cancer Res. 13(16), 4731-4739 (2007).
12. Kommoss F, Wolfle J, Bauknecht T et al.: Co-expression of M-CSF transcripts and protein, FMS (M-CSF receptor) transcripts and protien, and steroid receptor content in adenocarcinomas of the ovary. J. Pathol. 174(2), 111-119 (1994).
13. Takahashi K,Yoshida H,Sonoda S et al.: Expression of a rat ovary-independent mammary tumor-associated antigen defined by a monoclonal antibody, TAK-B1. Jpn J. Cancer Res. 82(5), 577-584 (1991).
14. Wolf NG, Abdul-Karim FW, Farver C et al.: Analysis of ovarian borderline tumors using comparative genomic hybridization and fluorescence in situ hybridization. Genes Chromosomes Cancer 25(4), 307-315 (1999).
15. Schena M, Shalon D, Davis RW, Brown PO: Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science 270(5235), 467-470 (1995).
16. Schena M, Shalon D, Heller R et al.: Parallel human genome analysis: microarray-based expression monitoring of 1000 genes. Proc. Natl Acad. Sci. USA 93(20), 10614-10619 (1996).
17. Lockhart DJ, Dong H, Byrne MC et al.: Expression monitoring by hybridization to high-density oligonucleotide arrays. Nat. Biotechnol. 14(13), 1675-1680 (1996).
18. Duggan DJ, Bittner M, Chen Y, Meltzer P, Trent JM: Expression profiling using cDNA microarrays. Nat. Genet. 21(Suppl. 1), 10-14 (1999).
19. Lipshutz RJ, Fodor SP, Gingeras TR, Lockhart DJ: High density synthetic oligonucleotide arrays. Nat. Genet. 21(Suppl. 1), 20-24 (1999).
20. Ismail RS, Baldwin RL, Fang J et al.: Differential gene expression between normal and tumor-derived ovarian epithelial cells. Cancer Res. 60(23), 6744-6749 (2000).
21. Wong KK, Cheng RS, Mok SC: Identification of differentially expressed genes from ovarian cancer cells by MICROMAX cDNA microarray system. Biotechniques 30(3), 670-675 (2001).
22. Matei D, Graeber TG, Baldwin RL et al.: Gene expression in epithelial ovarian carcinoma. Oncogene 21(41), 6289-6298 (2002).
23. Manderson EN, Mes-Masson AM, Novak J et al.: Expression profiles of 290 ESTs mapped to chromosome 3 in human epithelial ovarian cancer cell lines using DNA expression oligonucleotide microarrays. Genome Res. 12(1), 112-121 (2002).
24. Shridhar V, Lee J, Pandita A et al.: Genetic analysis of early- versus late-stage ovarian tumors. Cancer Res. 61(15), 5895-5904 (2001).
25. Kim JH, Skates SJ, Uede T et al.: Osteopontin as a potential diagnostic biomarker for ovarian cancer. JAMA 287(13), 1671-1679 (2002).
26. Kim JH, Herlyn D, Wong KK et al.: Identification of epithelial cell adhesion molecule autoantibody in patients with ovarian cancer. Clin. Cancer Res. 9 (13), 4782-4791 (2003).
27. Mok SC, Chao J, Skates S et al.: Prostasin, a potential serum marker for ovarian cancer: identification through microarray technology. J. Natl Cancer Inst. 93(19). 1458-1464 (2001).
28. Meinhold-Heerlein I, Bauerschlag D, Zhou Y et al.: An integrated clinical-genomics approach identifies a candidate multi-analyte blood test for serous ovarian carcinoma. Clin. Cancer Res. 13(2 Pt 1), 458-466 (2007).
29. Shedden KA, Kshirsagar MP, Schwartz DR et al.: Histologic type, organ of origin, and Wnt pathway status: effect on gene expression in ovarian and uterine carcinomas. Clin. Cancer Res. 11(6), 2123-2131 (2005).
30. Zorn KK, Bonome T, Gangi L et al.: Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer. Clin. Cancer Res. 11(18), 6422-6430 (2005).
31. Spentzos D, Levine DA, Ramoni MF et al.: Gene expression signature with independent prognostic significance in epithelial ovarian cancer. J. Clin. Oncol. 22(23), 4700-4710 (2004).
32. Berchuck A: Biomarkers in the ovary. J. Cell Biochem. 23, 223-226 (1995).
33. Howell NR, Zheng W, Cheng L et al.: Carcinomas of ovary and lung with clear cell features: can immunohistochemistry help in differential diagnosis? Int. J. Gynecol. Pathol. 26(2), 134-140 (2007).
34. Posadas EM, Davidson B, Kohn EC: Proteomics and ovarian cancer: implications for diagnosis and treatment: a critical review of the recent literature. Curr. Opin. Oncol. 16(5), 478-484 (2004).
35. Kamel-Reid S, Arrowsmith CH, Reis PP, Squire JA: Methods of molecular analysis. In: The Basic Science or Oncology. Tannock IF, Hill RP, Bristow RG, Harrington L (Eds). McGraw-Hill, NY, USA, 49-76 (2005).
36. Wulfkuhle JD, Liotta LA, Petricoin EF: Proteomic applications for the early detection of cancer. Nat. Rev. Cancer 3(4), 267-275 (2003).
37. Kavallaris M, Marshall GM: Proteomics and disease: opportunities and challenges. Med. J. Aust. 182(11), 575-579 (2005).
38. de Nictolis M, Garbisa S, Lucarini G et al.: 72-kilodalton type IV collagenase, type IV collagen, and Hi 67 antigen in serous tumors or the ovary: a clinicopathologic, immunohistochemical, and serological study. Int. J. Gynecol. Pathol. 15(2), 102-109 (1996).
39. Lee CJ, Ariztia EV, Fishman DA: Conventional and proteomic technologies for the detection of early stage malignancies: mackers for ovarian cancer. Crit. Rev. Clin. Lab Sci. 44(1), 87-114 (2007).
40. Ye B, Cramer DW, Skates SJ et al.: Haptoglobin-α subunit as potential serum biomarker in ovarian cancer: identification and characterization using proteomic profiling and mass spectrometry. Clin. Cancer Res. 9(8), 2904-2911 (2003).
41. Acs G, Pasha T, Zhang PJ: WT1 is differentially expressed in serous, endometrioid, clear cell, and mucinous carcinomas of the peritoneum, fallopian tube, ovary, and endometrium. Int. J Gynecol Pathol. 23(2), 110-118 (2004).
42. Semmes OJ, Feng Z, Adam BL et al.: Evaluation of serum protein profiling by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry for the detection of prostate cancer: I. Assessment of platform reproducibility Clin. Chem. 51(1), 102-112 (2005).
43. Petricoin EF, Ardekani AM, Hitt BA et al.: Use of proteomic patterns in serum to identify ovarian cancer. Lancet 359(9306), 572-577 (2002).
44. Zhu W, Wang X, Ma Y et al.: Detection of cancer-specific markers amid massive mass spectral data. Proc. Natl Acad. Sci. USA 100(25), 14666-14671 (2003).
45. Alexe G, Alexe S, Liotta LA et al.: Ovarian cancer detection by logical analysis Vof proteomic data. Proteomics 4(3), 766-783 (2004).
46. Petricoin EF, Belluco C, Araujo RP, Liotta LA: The blood peptidome: a higher dimension of information content for cancer biomarker discovery. Nat. Rev. Cancer 6(12), 961-967 (2006).
47. Beecher CWW: The human metabolome. In: Metabolic Profiling: Its Role in Biomarker Discovery and Gene Function Analysis. Harrigan GG, Goodacre R (Eds). Kluwer Academic Publishers, MA, USA 311-320 (2003).
48. Maruvada P, Wang W, Wagner PD, Srivastava S: Biomarkers in molecular medicine: cancer detection and diagnosis. Biotechniques (Suppl.) 9-15 (2005).
49. Vang R, Gown AM, Farinola M et al.: p16 expression in primary ovarian mucinous and endometrioid tumors and metastatic adenocarcinomas in the ovary: utility for identification of metastatic HPV-related endocervical adenocarcinomas. Am. J. Surg. Pathol. 31(5), 653-663 (2007).
50. Wishart DS, Tzur D, Knox C et al.: HMDB: the Human Metabolome Database. Nucleic Acids Res. 35(Database issue), D521-D526 (2007).
51. Griffin JL, Nicholls AW.' Metabolomics as a functional genomic tool for understanding hpid clysfunction in diabetes, obesity and related disorders. Pharmacogenomics 7 (7), 1095-1107 (2006).
52. Lindon JC, Holmes E, Nicholson JK: Metabonomics in pharmaceutical R&D. FEBS J. 274(5),1140-1151 (2007).
53. Mol BW, Boll D, de Kanter M et al.: Distinguishing the benign and malignant adnexal mass: an external validation of prognostic models. Gynecol. Oncol. 80(2), 162-167 (2001).
54. Farhi J, Jacobs HS: Early prediction of ovarian multifollicular response during ovulation induction in patients with polycystic ovary syndrome. Fertil. Steril. 67(3), 459-462 (1997).
55. Gallion H, van Nagell JR Jr, Donaldson ES, Hanson MB, Powell DF: Immature teratoma of the ovary. Am. J Obstet. Gynecol. 146(4), 361-365 (1983).
56. Suzuki M, Tamura N, Kobayashi H et al.: Clinical significance of combined use of macrophage colony-stimulating factor and squamous cell carcinoma antigen as a selective diagnostic marker for squamous cell carcinoma arising in mature cystic teratoma of the ovary. Gynecol. Oncol. 77 (3), 405-409 (2000).
57. Einhorn N, Knapp RC, Bast RC, Zurawski VR Jr: CA 125 assay used in conjunction with CA 15-3 and TAG-72 assays for discrimination between malignant and non-malignant diseases of the ovary. Acta Oncol. 28(5), 655-657 (1989).
58. Hayashi H, Yaginuma Y, KItamura S et al.: Bilateral oophorectomy in asymptomatic women over 50 years old selected by ovarian cancer screening. Gynecol. Obstet. Invest. 47(1), 58-64 (1999).
59. Buys SS, Partridge E, Greene MH et al.: Ovarian cancer screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial: findings from the initial screen of a randomized trial. Am. J. Obstet Gynecol. 193(5), 1630-1639 (2005).
60. Menon U, Skates-SJ, Lewis S et al.: Prospective study using the risk of ovarian cancer algorithm to screen for ovarian cancer. J. Clin. Oncol. 23(31), 7919-7926 (2005).
61. Skates SJ, Xu FJ, Yu YH et al.: Toward an optimal algorithm for ovarian cancer screening with longitudinal tumor markers. Cancer76(Suppl. 10), 2004-2010 (1995).
62. Boulman N, Levy Y, Leiba R et al.: Increased C-reactive protein levels in the polycystic ovary syndrome: a marker of cardiovascular disease. J. Clin. Endocrinol. Metab. 89(5), 2160-2165 (2004).
63. Zhang Z, Bast RC, Jr., Yu Y et al.: Three biomarkers identified from seruin proteomic analysis for the detection of early stage ovarian cancer. Cancer Res. 64(16), 5882-5890 (2004).
64. Skates SJ, Horick N, Yu Yu et al.: Preoperative sensitivity and specificity for early-stage ovarian cancer when combining cancer antigen CA- 125II, CA 15-3, CA 72-4, and macrophage colony-stimulating factor using mixtures of multivariate normal distributions. J. Clin. Oncol. 22(20), 4059-4066 (2004).
65. Huang CY, Cheng WF, Lee CN et al.: Serum mesothelin In epithelial ovarian carcinoma: a new screening marker and prognostic factor. Anticancer Res. 26 (6C), 4721-4728(2006).
66. Badgwell D, Lu Z, Cole L et al.: Urinary mesothelin provides greater sensitivity for early stage ovarian cancer than serum mesothelin, urinary hCG free β subunit and urinary hCG β core fragment. Gynecol. Oncol. 106(3), 490-497 (2007).
67. Wang P, Wu X, Chen W, Liu J, Wang X: The lysophosphatidic acid (LPA) receptors their expression and significance in epithelial ovarian neoplasms. Gynecol. Oncol. 104(3), 714-720 (2007).
68. Sutphen R, Xu Y, Wilbanks GD et al.: Lysophosphollpids are potential biornarkers of ovarian cancer. Cancer Epidemiol. Biomarker Prev. (13), 1185-1191 (2004).
69. Rosen DG, Wang L, Atkinson JN et at.: Potential markers that complement expression of CAI 25 in epithelial ovarian cancer. Gynecol. Oncol. 99(2), 267-277 (2005).
70. Hellstrom 1, Raycraft J, Hayden-Ledbetter M etal: The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res. 63(13), 3695-3700 (2003).
71. Bast RC Jr, Badgwell D, Lu Z et al.: New tumor markers: CA125 and beyond. Int. J Gynecol Cancer 15 (Suppl.), 3274-3281 (2005).
72. Rustin QJ, Bast RC, Jr., Kelloff GJ et al.: Use of CA-125 in clinical trial evaluation of new therapeutic drugs for ovarian cancer. Clin. Cancer Res. 10(11), 3919-3926 (2004).
73. Rustin QJ, Nelstrop AE, Bentzen SM, Bond SJ, McClean P: Selection of active drugs for ovarian cancer based on CA-125 and standard response rates in Phase II trials. J. Clin. Oncol. 18(8), 1733-1739 (2000).
74. Schuijer M, Berns EM: TP53 and ovarian cancer. Hum. Mutat. 21(3), 285-291 (2003).
75. Selvakumaran M, Pisarcik DA, Bao, R, Yeung AT, Hamilton TC: Enhanced cisplatin cytotoxicity by disturbing the nucleotide excision repair pathway in ovarian cancer cell lines. Cancer Res. 63(6), 1311-1316 (2003).
76. Safaei R: Role of copper transporters in the uptake and efflux of platinum containing drugs. Cancer Lett. 234(1), 34-39 (2006).
77. Mansouri A, Zhang Q, Ridgway LD, Tian L, Claret FX: Cisplatin resistance in an ovarian carcinoma is associated with a defect in programmed cell death control through XIAP regulation. Oncol. Res. 13(6-10), 399-404 (2003).
78. Hille S, Rein DT, Riffelmann M et al.: Anticancer drugs induce mdr1 gene expression in recurrent ovarian cancer. Anticancer Drugs. 17(9), 1041-1044 (2006).
79. Wang Y, O'Brate A, Zhou W, Giannakakou P: Resistance to microtubule-stabilizing drugs involves two events: β-tubulin mutation in one allele followed by loss of the second allele. Cell Cycle 4(12), 1847-1853 (2005).
80. Komatsu M, Hiyama K, Tanimoto K et al.: Prediction of individual response to platinum/paclitaxel combination using novel marker genes in ovarian cancers. Mol. Cancer Ther. 5(3), 767-775 (2006).
81. Hunter VJ, Daly L, Helms M et al.: The prognostic significance of CA 125 half-life in patients with ovarian cancer who have received primary chemotherapy after surgical cytoreduction. Am. J. Obstet. Cynecol. 163(4 Pt 1), 1164-1167 (1990).
82. Bonafe N, Gilmore-Hebert M, Folk NL et al.: Glyceraldehyde-3-phosphate dehydrogenase binds to the AU-Rich 3′ untranslated region of colony-stimulating factor-1 (CSF-1) messenger RNA in human ovarian cancer cells: possible role in CSF-1 posttranscriptional regulation and tumor phenotype. Cancer Res. 65(9), 3762-3771 (2005).
83. Toy EP, Chambers. JT, Kacinski BM, Flick MB, Chambers SK: The activated macrophage colony-stimulating factor (CSF-1) receptor as a predictor of poor outcome in advanced epithelial ovarian carcinoma. Gynecol. Oncol. 80(2), 194-200 (2001).
84. Price FV, Chambers SK, Chambers JT et al.: Colony-stimulating factor-1 in primary ascites of ovarian cancer is a significant predictor of survival. Am. J. Obstet. Gynecol. 168(2), 520-527 (1993).
85. Kleinberg L, Florenes VA, Silins I et al.: Nuclear expression of survivin is associated with improved survival in metastatic ovarian carcinoma. Cancer 109(2), 228-238 (2007).
86. Hogdall EV, Christensen L, Kjaer SK et al.: Distribution of HER-2 overexpression in ovarian carcinoma tissue and its prognostic value in patients with ovarian carcinoma: from the Danish MALOVA Ovarian Cancer Study. Cancer 98(1), 66-73 (2003).
87. Sasaki N, Kudoh K, Kita T et al.: Effect of HER-2/neu overexpression on chemoresistance and prognosis in ovarian carcinoma. J. Obstet. Gynaecol. Res. 33(1), 17-23 (2007).
88. Lenhard M, Kuemper C, Ditsch N et al.: Use of novel serum markers in clinical follow-up of Sertoli-Leydig cell tumours. Clin. Chem. Lab. Med. 45(5), 657-661 (2007).
89. Patterson DM, Rustin GJ: Controversies in the management of germ cell tumours of the ovary. Curr. Opin. Oncol. 18(5), 500-506 (2006).
90. Tsukishiro S, Suzumori N, Nishikawa H, Arakawa A, Suzumori K: Use of serum secretory leukocyte protease inhibitor levels in patients to improve specificity of ovarian cancer diagnosis. Gynecol Oncol. 96(2), 516-519 (2005).
91. Hogdall EV, Hogdall CK, Tingulstad S et al.: Predictive values of serum tumour markers tetranectin, OVX1, CASA and CA125 in patients with a pelvic mass. Int. J. Cancer 89(6), 519-523 (2000).
92. van Haaften-Day C, Shen Y, Xu F et al.: OVX1, macrophage-colony stimulating factor, and CA-125-II as tumor markers for epithelial ovarian carcinoma: a critical appraisal, Cancer 92(11), 2837-2844 (2001).
93. Moore LE, Fung ET, McGuire M et al.: Evaluation of apolipoprotein A1 and posttranstationally modified forms of transthyretin as biomarkers for ovarian cancer detection in an independent study population. Cancer Epidemiol. Biomarkers Prev. 15(9), 1641-1646 (2006).
94. Kozak KR, Su F, Whitelegge JP et al.: Characterization of serum blomarkers for detection of early stage ovarian cancer. Proteomics 5(17), 4589-4596 (2005).
95. Simon I, Liu Y, Krall KL et al.: Evaluation of the novel serum markers B7-H4, Spondin 2, and DcR3 for diagnosis and early detection of ovarian cancer. Gynecol Oncol. 106(1), 112-118 (2007).
96. Simon I, Katsaros D, Rigault de la Longrais I et al.: B7-H4 is over-expressed In early-stage ovarian cancer and is independent of CA125 expression. Gynecol. Oncol. 106(2), 334-341 (2007).
97. Yesilada E, Sabin I, Ozcan H et al.: Increased micronucleus frequencies in peripheral blood lymphocytes in women with polycystic ovary syndrome. Eur. J. Endocrinol. 154(4), 563-568 (2006).
98. Malamou-Mitsi V, Crikoni O, Timotheadou E et al.: Prognostic significance of HER-2, p53 and Bcl-2 in patients with epithelial ovarian cancer. Anticancer Res. 27(2), 1157-1165 (2007).
99. Sorak M, Arsenijevic S, Lukic G et al.: Relationship of serum levels of tumor markers with tissue expression of gene products in ovarian carcinoma. J. Buon. 12(1), 99-104 (2007).
100. Kikkawa F, Nawa A, Kajiyama H et al.: Clinical characteristics and prognosis of mucinous tumors of the ovary. Gynecol. Oncol. 103(1), 171-175 (2006).
101. Gronlund B, Hogdall EV, Christensen IJ et al.: Pre-treatment prediction of chemoresistance in second-line chemotherapy of ovarian carcinoma: value of serological tumor marker determination (tetranectin, YKL-40, CASA, CA 125). Int. J Biol. Markers. 21(3), 141-148 (2006).
102. Sehouli J, Akdogan Z, Heinze T et al.: Preoperative determination of CASA (Cancer Associated Serum Antigen) and CA-125 for the discrimination between benign and malignant pelvic tumor mass: a prospective study. Anticancer Res. 23 (2A), 1115-1118 (2003).
103. Lu KH, Patterson AP, Wang L et al.: Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis. Clin. Cancer Res. 10(10), 3291-3300 (2004).
104. Heinzelmann-Schwarz VA, Gardiner-Garden M, Henshall SM et al.: Overexpression of the cell adhesion molecules DDR1, Claudin 3, and Ep-CAM in metaptastic ovarian epithelium and ovarian cancer. Clin. Cancer Res. 10(13), 4427-4436 (2004).
105. Samimi G, Safaei R, Katano K et al.: Increased expression of the copper efflux transporter ATP7A mediates resistance to cisptatin, carboplatin, and oxaliplatin in ovarian cancer cells. Clin. Cancer Res. 10(14), 4661-4669 (2004).
106. Samimi G, Varki NM, Wilczynski S et al.: Increase in expression of the copper transporter ATP7A during platinum drug-based treatment is associated with poor survival in ovarian cancer patients. Clin. Cancer Res. 9(16 Pt 1), 5853-5859 (2003).
107. Lin YG, Han LY, Kamat AA et al.: EphA2 overexpression is associated with angiogenesis in ovarian cancer. Cancer 109(2), 332-340 (2007).
108. Thaker PH, Deavers M, Celestino J et al.: EphA2 expression is associated with aggressive features in ovarian carcinoma. Clin. Cancar Res. 10(15), 5145-5150 (2004).
109. Kang S, Ju W, Kim JW et al.: Association between excision repair cross-complementation group 1 polymorphism and clinical outcome of platinum-based chemotherapy in patients with epithelial ovarian cancer. Exp. Mol. Med. 38(3), 320-324 (2006).
110. Birrer MJ, Johnson ME, Hao K et al.: Whole genome oligonucleotide-based array comparative genomic hybridization analysis identified fibroblast growth factor 1 as a prognostic marker for advanced-stage serous ovarian adenocarcinomas. J. Clin. Oncol. 25(16), 2281-2287 (2007).
111. Gan Y, Wientjes MG, Au JL: Expression of basic fibroblast growth factor correlates with resistance to paclitaxel in human patient tumors. Pharm. Res. 23(6), 1324-1331 (2006).
112. Osada R, Horiuchi A, Kikuchi N et al.: Expression of hypoxia-inducible factor 1α, hypoxia-inducible factor 2α, and von Hippel-Lindau protein in epithelial ovarian neoplasms and allelic loss of von Hippel-Lindau gene: nuclear expression of hypoxia-inducible factor 1α is an independent prognostic factor in ovarian carcinoma. Hum. Pathol. 38(9), 1310-1320 (2007).
113. Takao M, Okamoto A, Nikaido T et al.: Increased synthesis of indoleamine-2,3-dioxygenase protein is positively associated with impaired survival in patients with serous-type, but not with other types of, ovarian cancer. Oncol. Rep. 17(6), 1333-1339 (2007).
114. Okamoto A, Nikaido T, Ochiai K et al.: Indoleamine 2,3-dioxygenase serves as a marker of poor prognosis in gene expression profiles of serous ovarian cancer cells. Clin. Cancer Res. 11(16), 6030-6039 (2005).
115. Maatta M, Talvensaari-Mattila A, Turpeenniemi-Hujanen T, Santala M: Matrix metalloproteinase-2 (MMP-2) and -9 (MMP-9) and their tissue inhibitors (TIMP-1 and TIMP-2) in differential diagnosis between low malignant potential (LMP) and malignant ovarian tumours. Anticancer Res. 27(4C), 2753-2758 (2007).
116. Sillanpaa S, Anttila M, Voutilainen K et al.: Prognostic significance of matrix metalloproteinase-9 (MMP-9) in epithelial ovarian cancer. Gynecol. Oncol. 104(2), 296-303 (2007).
117. Samanta AK, Huang HJ, Bast RC Jr, Liao WS: Overexpression of MEKK3 confers resistance to apoptosis through activation of NFκB. J. Biol. Chem. 279(9), 7576-7583 (2004).
118. Wang L, Ma J, Liu F et al.: Expression of MUC1 in primary and metastatic human epithelial ovarian cancer and its therapeutic significance. Gynecol. Oncol. 105(3), 695-702 (2007).
119. Nomura H, Tamada Y, Miyagi T et al.: Expression of NEU3 (plasma membrane-associated sialidase) in clear cell adenocarcinoma of the ovary: its relationship with T factor of pTNM classification. Oncol. Res. 16(6), 289-297 (2006).
120. Ouellet V, Le Page C, Guyot MC et al.: SET complex in serous epithelial ovarian cancer. Int. J. Cancer 119(9), 2119-2126 (2006).
121. Schorge JO, Drake RD, Lee H et al.: Osteopontin as an adjunct to CA125 in detecting recurrent ovarian cancer. Clin. Cancer Res. 10(10), 3474-3478 (2004).
122. Nakae M, Iwamoto I, Fujino T et al.: Preoperative plasma osteopontin level as a biomarker complementary to carbohydrate antigen 125 in predicting ovarian cancer. J. Obstet. Gynaecol. Res. 32(3), 309-314 (2006).
123. Baron AT, Boardman CH, Latky JM et al.: Soluble epidermal growth factor receptor (sEGFR) [corrected] and cancer antigen 125 (CA125) as screening and diagnostic tests for epithelial ovarian cancer. Cancer Epidemiol. Biomarkers Prev. 14(2), 306-318 (2005).
124. Secord AA, Darcy KM, Hutson A et al.: Co-expression of angiogenic markers and associations with prognosis in advanced epithelial ovarian cancer: a Gynecologic Ontology Group study. Gynecol. Oncol. 106(1), 221-232 (2007).
125. Kuhn W, Marx D, Meidel A et al.: Borderline tumors of the ovary: a clinico-pathologic and immunohistochemical study of 54 cases. J. Obstet. Gynaecol. Res. 24(6), 437-445 (1998).
126. Mills GB, Bast RC Jr, Srivastava S: Future for ovarian cancer screening: novel markers from emerging technologies of transcriptional profiling and proteomics. J. Natl Cancer Int. 93(19), 1437-1439 (2001).
127. Tsigkou A, Marrelli D, Reis FM et al.: Total inhibin is a potential serum marker for epithelial ovarian cancer. J. Clin. Endocrinol. Metab. 92(7), 2526-2531 (2007).
128. Baba T, Mori S, Matsumura N et al.: Trophinin is a potent prognostic marker of ovarian cancer involved in platinum sensitivity. Biocbem. Biophys. Res. Commun. 360(2), 363-369 (2007).
129. Paju A, Vartiainen J, Haglund C et al.: Expression of trypsinogen-1, trypsinogen-2, and tumor-associated trypsin inhibitor in ovarian cancer: prognostic study on tissue and serum. Clin. Cancer Res. 10(14), 4761-4768 (2004).
130. Mozzetti S, Ferlini C, Concolino P et al.: Class III β-tubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients. Clin. Cancer Res. 11 (1), 298-305 (2005).
131. Ahmed AS, Dew T, Lawton FG et al.: M2-PK as a novel marker in ovarian cancer. A prospective cohort study. Eur. J. Gynaecol. Oncol. 28(2), 83-88 (2007).
132. Orbo A, Hanevik M, Jaeger R, van Heusden S, Sager G: Urinary cyclic GMP after treatment of gynecological cancer. A prognostic marker of clinical outcome. Anticancer Res. 27(4C), 2591-2596 (2007).
133. Muller-Klingspor V, Hefler L, Obermair A et al.: Prognostic value of β1-integrin (=CD29) in serous adenocarcinomas of the ovary. Anticancer Res. 21(3C), 2185-2188 (2001).
134. Dupont J, Tanwar MK, Thaler HT et al.: Early detection and prognosis of ovarian cancer using serum YKL-40. J. Clin. Oncol. 22(16), 3330-3339 (2004).
135. Dehn H, Hogdall EV, Johansen JS et al.: Plasma YKL-40, as a prognostic tumor marker in recurrent ovarian cancer. Acta Obstet. Gynecol. Scand. 82(3), 287-293 (2003).